1. 首页
  2. ›Wells Fargo Q3: AstraZeneca Rises to Top Holding, NVIDIA Stake Increased by Over 10%

Wells Fargo Q3: AstraZeneca Rises to Top Holding, NVIDIA Stake Increased by Over 10%

N
nashnova research
·今天发布·阅读约 9 分钟

Wells Fargo's Q3 13F shows total holdings at ~$640 billion. UK pharma giant AstraZeneca jumped from near-zero weight to the No. 1 position in a single quarter, while Nvidia saw a 10.5% stake increase — the bank's chips are shifting from pure tech to a pharma-plus-tech dual axis.

01

How did AstraZeneca go from nowhere to No. 1 in one quarter?

•
AstraZeneca ended the quarter at ~$26.41 billion in market value, 4.10% of the portfolio — up from just 0.05% last quarter. That 4.05-percentage-point single-quarter jump knocked Apple off the top spot.
•
This means → Wells Fargo executed an extremely concentrated build in Q3, large enough to vault a single name straight to the top.
•
In plain terms = last quarter they barely held any; this quarter it became their biggest bet — not gradual accumulation, but a single heavy move.
02

Is the tech allocation growing or shrinking?

•
Nvidia rose from ~58.86 million shares to ~65.05 million, a 10.51% increase. Quarter-end value: ~$14.86 billion, ranked fifth, and one of the top five buys of the quarter.
•
Microsoft holdings grew 2.96% to ~$17.65 billion, holding steady at third.
•
Apple slipped to second but shed only 0.24% of its shares, valued at ~$19.90 billion — less an active trim than a relative-ranking shift caused by AstraZeneca's surge.
•
This means → all three mega-cap tech names saw net additions; Nvidia's was the most aggressive. Apple "losing the top spot" is a ranking story, not a conviction story.
03

What do the ETF and options positions signal?

•
Fourth-largest holding S&P 500 ETF (IVV) dipped 0.72% in share count. Positions six through ten: S&P Total Market ETF (ITOT), Alphabet, MSCI EAFE ETF (IEFA), S&P 500 ETF (SPY), and Broadcom.
•
The options book is more telling: Nasdaq-100 ETF call options declared at ~$6.06 billion, Russell 2000 ETF put options at ~$5.77 billion — both saw significant weight increases and both ranked among the top five buys.
•
In plain terms = buying large-cap tech calls for upside while buying small-cap puts for protection — a classic "bullish big-cap, hedge small-cap" combo.
04

What was trimmed or exited?

•
Top five sells: Visa, S&P 500 ETF put options, SanDisk, Vanguard Mid-Cap ETF, and iShares Russell Mid-Cap ETF.
•
Vanguard Mid-Cap ETF saw the steepest cut at 10.45% — the largest trim among the top 20 holdings.
•
The fund opened 551 new positions (mostly options; the largest was Moderna call options at ~$462 million) and exited 514 — high activity on both sides, with an overall turnover rate of 13.94%.
05

What does the overall portfolio picture tell us?

•
Quarter-end total market value: ~$640 billion, up ~3.23% from last quarter — but much of that ~$20 billion increase reflects price appreciation in existing holdings, not equivalent net inflows.
•
Top-ten concentration sits at 22.12% — not especially high, indicating a still-diversified book.
•
This reflects a Q3 playbook of "add pharma (AstraZeneca), add chips (Nvidia), trim mid-and-small-caps, and use options for directional hedging." The key variables for the next 13F: whether AstraZeneca's weight surge persists, and whether the Nvidia build extends further in Q4.

市场有风险,内容仅供研究参考,不构成投资建议。

相关标的

4
  • AstraZenecaAZN.US-0.2%

    Wells Fargo elevated AstraZeneca to its top holding in Q3, with its portfolio weight jumping 4.05 percentage points in a single quarter, directly driven by large institutional capital inflows.

  • NVIDIANVDA.US-4.1%

    Wells Fargo increased its NVIDIA position by 10.51% in Q3, making it one of the top five purchases, reflecting continued institutional accumulation in the AI chip space.

  • AppleAAPL.US-1%

    Displaced from the top spot by AstraZeneca with a slight 0.24% reduction in holdings, Wells Fargo's allocation weight to Apple declined relatively.

  • Vanguard Mid Cap ETFVO.ETF-1.4%

    Wells Fargo trimmed its position by 10.45% in Q3, the largest reduction among its top 20 holdings, reflecting institutional pullback from mid-cap exposure.